Literature DB >> 8065503

Evidence that lithium induces a glutamatergic: nitric oxide-mediated response in rat brain.

B H Harvey1, M E Carstens, J J Taljaard.   

Abstract

Studies have indicated the involvement of a glutamatergic mechanism in lithium (Li+) action. Glutamatergic agonists, such as kainic acid, are known to promote the synthesis of nitric oxide (NO) and to increase cGMP, while Li+ has displayed a similar, yet unexplained, ability to increase cGMP. NO synthesis is regarded as the principal prodromal event leading to the activation of the guanyl cyclase-cGMP transduction mechanism. In the present study, the involvement of the NO:cGMP pathway in the action of Li+ was examined, while the possibility of a glutamatergic mechanism in this response was also investigated. Parameters examined included cortical accumulation of cGMP and the stable oxidative metabolites of NO, viz. NO2- and NO3-, collectively expressed as NO2-. A significant positive correlation was observed in the in vivo cGMP and NO2- data throughout all the groups. Chronic treatment of rats with LiCl (0.3% m/m) engendered a significant increase in cGMP levels which was inhibited by the NO-synthase (NOS) inhibitor, N-nitro-L-arginine methyl ester (L-NAME). Acute administration of kainic acid resulted in an increased accumulation of NO2-, also prevented by concomitant L-NAME administration. In addition, a synergistic stimulatory response on cortical NO2- was observed in the combination of LiCl and kainic acid. Collectively, these data implicate an involvement of a glutamatergic-mediated NO:cGMP transduction mechanism in the action of Li+.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8065503     DOI: 10.1007/bf00967326

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  30 in total

1.  Regional distribution of EDRF/NO-synthesizing enzyme(s) in rat brain.

Authors:  U Förstermann; L D Gorsky; J S Pollock; H H Schmidt; M Heller; F Murad
Journal:  Biochem Biophys Res Commun       Date:  1990-04-30       Impact factor: 3.575

Review 2.  Biosynthesis and metabolism of endothelium-derived nitric oxide.

Authors:  L J Ignarro
Journal:  Annu Rev Pharmacol Toxicol       Date:  1990       Impact factor: 13.820

Review 3.  Distribution and regulation of cyclic GMP in the central nervous system.

Authors:  J A Ferrendelli
Journal:  Adv Cyclic Nucleotide Res       Date:  1978

4.  A novel hypothesis for the psycho-modulating effects of lithium: the role of essential fatty acids, eicosanoids and sub-cellular second messengers.

Authors:  B H Harvey; M E Carstens; J J Taljaard
Journal:  Med Hypotheses       Date:  1990-05       Impact factor: 1.538

5.  Determination of adenosine 3':5'-cyclic monophosphate in cerebral tissues by saturation analysis. Assessment of a method using a binding protein from ox muscle.

Authors:  M Weller; R Rodnight; D Carrera
Journal:  Biochem J       Date:  1972-08       Impact factor: 3.857

6.  Nitric oxide synthase: irreversible inhibition by L-NG-nitroarginine in brain in vitro and in vivo.

Authors:  M A Dwyer; D S Bredt; S H Snyder
Journal:  Biochem Biophys Res Commun       Date:  1991-05-15       Impact factor: 3.575

7.  Kainate receptors coupled to the evoked release of [3H]-gamma-aminobutyric acid from striatal neurons in primary culture: potentiation by lithium ions.

Authors:  S Weiss; D E Kemp; L Bauce; F W Tse
Journal:  Mol Pharmacol       Date:  1990-08       Impact factor: 4.436

8.  Role of intercellular and intracellular communication by nitric oxide in coupling of muscarinic receptors to activation of guanylate cyclase in neuronal cells.

Authors:  J Hu; E E el-Fakahany
Journal:  J Neurochem       Date:  1993-08       Impact factor: 5.372

9.  Two pathways of cyclic GMP production through glutamate receptor-mediated nitric oxide synthesis.

Authors:  D Okada
Journal:  J Neurochem       Date:  1992-10       Impact factor: 5.372

Review 10.  Measurement of nitric oxide in biological models.

Authors:  S Archer
Journal:  FASEB J       Date:  1993-02-01       Impact factor: 5.191

View more
  9 in total

1.  Lithium increases nitric oxide levels in subjects with bipolar disorder during depressive episodes.

Authors:  Rafael T de Sousa; Marcus V Zanetti; Geraldo F Busatto; Margaret G Mouro; Carlos A Zarate; Wagner F Gattaz; Elisa M Higa; Rodrigo Machado-Vieira
Journal:  J Psychiatr Res       Date:  2014-04-12       Impact factor: 4.791

2.  Early suppression of striatal cyclic GMP may predetermine the induction and severity of chronic haloperidol-induced vacous chewing movements.

Authors:  A M Bester; B H Harvey
Journal:  Metab Brain Dis       Date:  2000-12       Impact factor: 3.584

Review 3.  Effects of lithium on inflammation.

Authors:  Ahmad Nassar; Abed N Azab
Journal:  ACS Chem Neurosci       Date:  2014-05-06       Impact factor: 4.418

4.  Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies.

Authors:  C B Brink; J D Clapton; B E Eagar; B H Harvey
Journal:  J Neural Transm (Vienna)       Date:  2007-09-07       Impact factor: 3.575

5.  Protective effects of lithium on acetic acid-induced colitis in rats.

Authors:  Ali Daneshmand; Reza Rahimian; Hamed Mohammadi; Shahram Ejtemaee-Mehr; Seyed Mohammad Tavangar; Roohollah Babaei Kelishomi; Ahamd Reza Dehpour
Journal:  Dig Dis Sci       Date:  2008-12-10       Impact factor: 3.199

Review 6.  A Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical Correlates.

Authors:  Sarel J Brand; Marisa Moller; Brian H Harvey
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

Review 7.  Lithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics.

Authors:  M Alda
Journal:  Mol Psychiatry       Date:  2015-02-17       Impact factor: 15.992

Review 8.  Roles of Gasotransmitters in Synaptic Plasticity and Neuropsychiatric Conditions.

Authors:  Ulfuara Shefa; Dokyoung Kim; Min-Sik Kim; Na Young Jeong; Junyang Jung
Journal:  Neural Plast       Date:  2018-05-06       Impact factor: 3.599

Review 9.  The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.

Authors:  Esmé Jansen van Vuren; Stephan F Steyn; Christiaan B Brink; Marisa Möller; Francois P Viljoen; Brian H Harvey
Journal:  Biomed Pharmacother       Date:  2021-01-01       Impact factor: 6.529

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.